Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.23
TBUFF's Cash to Debt is ranked higher than
50% of the 1158 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.03 vs. TBUFF: 0.23 )
TBUFF' s 10-Year Cash to Debt Range
Min: 0.23   Max: No Debt
Current: 0.23

Equity to Asset 0.57
TBUFF's Equity to Asset is ranked higher than
67% of the 965 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.58 vs. TBUFF: 0.57 )
TBUFF' s 10-Year Equity to Asset Range
Min: 0.39   Max: 0.93
Current: 0.57

0.39
0.93
F-Score: 4
Z-Score: 2.06
M-Score: -0.68
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -15.40
TBUFF's Operating margin (%) is ranked higher than
52% of the 1107 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.08 vs. TBUFF: -15.40 )
TBUFF' s 10-Year Operating margin (%) Range
Min: -101.12   Max: 27.69
Current: -15.4

-101.12
27.69
Net-margin (%) -33.66
TBUFF's Net-margin (%) is ranked higher than
50% of the 1107 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.46 vs. TBUFF: -33.66 )
TBUFF' s 10-Year Net-margin (%) Range
Min: -94.39   Max: 28.68
Current: -33.66

-94.39
28.68
ROE (%) -38.03
TBUFF's ROE (%) is ranked higher than
51% of the 1135 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.08 vs. TBUFF: -38.03 )
TBUFF' s 10-Year ROE (%) Range
Min: -192.91   Max: 32.96
Current: -38.03

-192.91
32.96
ROA (%) -17.64
TBUFF's ROA (%) is ranked higher than
52% of the 1169 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.54 vs. TBUFF: -17.64 )
TBUFF' s 10-Year ROA (%) Range
Min: -103.43   Max: 29.1
Current: -17.64

-103.43
29.1
ROC (Joel Greenblatt) (%) -243.95
TBUFF's ROC (Joel Greenblatt) (%) is ranked higher than
50% of the 1164 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.30 vs. TBUFF: -243.95 )
TBUFF' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -540.86   Max: 122.99
Current: -243.95

-540.86
122.99
Revenue Growth (3Y)(%) 10.10
TBUFF's Revenue Growth (3Y)(%) is ranked higher than
78% of the 948 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.80 vs. TBUFF: 10.10 )
TBUFF' s 10-Year Revenue Growth (3Y)(%) Range
Min: -4.4   Max: 38.7
Current: 10.1

-4.4
38.7
EBITDA Growth (3Y)(%) -15.70
TBUFF's EBITDA Growth (3Y)(%) is ranked higher than
59% of the 846 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.60 vs. TBUFF: -15.70 )
TBUFF' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: 18.6
Current: -15.7

0
18.6
EPS Growth (3Y)(%) 52.60
TBUFF's EPS Growth (3Y)(%) is ranked higher than
96% of the 822 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.10 vs. TBUFF: 52.60 )
TBUFF' s 10-Year EPS Growth (3Y)(%) Range
Min: 0   Max: 52.6
Current: 52.6

0
52.6
» TBUFF's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with TBUFF

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 2.90
TBUFF's P/B is ranked higher than
73% of the 1283 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.20 vs. TBUFF: 2.90 )
TBUFF' s 10-Year P/B Range
Min: 0.78   Max: 77
Current: 2.9

0.78
77
P/S 4.40
TBUFF's P/S is ranked higher than
66% of the 1283 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.25 vs. TBUFF: 4.40 )
TBUFF' s 10-Year P/S Range
Min: 1   Max: 83
Current: 4.4

1
83
Current Ratio 0.82
TBUFF's Current Ratio is ranked lower than
54% of the 1028 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.23 vs. TBUFF: 0.82 )
TBUFF' s 10-Year Current Ratio Range
Min: 0.73   Max: 11.15
Current: 0.82

0.73
11.15
Quick Ratio 0.70
TBUFF's Quick Ratio is ranked lower than
51% of the 1028 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.70 vs. TBUFF: 0.70 )
TBUFF' s 10-Year Quick Ratio Range
Min: 0.58   Max: 10.39
Current: 0.7

0.58
10.39
Days Inventory 48.53
TBUFF's Days Inventory is ranked higher than
92% of the 1283 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 141.66 vs. TBUFF: 48.53 )
TBUFF' s 10-Year Days Inventory Range
Min: 46.89   Max: 246.69
Current: 48.53

46.89
246.69
Days Sales Outstanding 44.87
TBUFF's Days Sales Outstanding is ranked higher than
88% of the 1283 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 89.68 vs. TBUFF: 44.87 )
TBUFF' s 10-Year Days Sales Outstanding Range
Min: 11.1   Max: 168.21
Current: 44.87

11.1
168.21

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 1.10
TBUFF's Price/Median PS Value is ranked higher than
87% of the 1283 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.50 vs. TBUFF: 1.10 )
TBUFF' s 10-Year Price/Median PS Value Range
Min: 0.32   Max: 24.3
Current: 1.1

0.32
24.3
Earnings Yield (Greenblatt) -2.60
TBUFF's Earnings Yield (Greenblatt) is ranked higher than
52% of the 1156 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.90 vs. TBUFF: -2.60 )
TBUFF' s 10-Year Earnings Yield (Greenblatt) Range
Min: -2.6   Max: 28.6
Current: -2.6

-2.6
28.6

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare: » details
Traded in other countries:TRX.Canada,
Tribute Pharmaceuticals Canada Inc was incorporated under the Business Corporations Act (Ontario) on November 14, 1994. The Company is a specialty pharmaceutical company. It conducts acquisition, licensing, development and promotion of healthcare products in Canada. It sells Uracyst and NeoVisc internationally through a number of strategic partnerships. The Company's portfolio of assets includes nine product lines, eight of which are on the market in Canada, including: NeoVisc, NeoVisc Single Dose, Uracyst, BladderChek, Bezalip SR, Soriatane, Cambia, Daraprim, Collatamp G, and MycoVa. The Company markets its products in Canada through its own sales force and currently has licensing agreements for the distribution of select products in over 20 countries, and continues to expand this footprint. It faces product competition from companies marketing competing pharmaceutical products and medical devices in Canada. The Company's operations are or may be subject to various federal, provincial, state and local laws, regulations and recommendations relating to the marketing of products and relationships with treating physicians, data protection, safe working conditions, laboratory and manufacturing practices, the export of products to certain countries and the purchase, storage, movement, use and disposal of hazardous or potentially hazardous substances.
» More Articles for TBUFF

Headlines

Articles On GuruFocus.com
Tribute Pharmaceuticals Provides Update of 2014 Revenues; Anticipates Fourth Quarter Revenue Growth Jan 27 2015 
CORRECTION FROM SOURCE: Tribute Pharmaceuticals Schedules Third Quarter 2014 Financial Results Confe Nov 03 2014 
Tribute Pharmaceuticals Schedules Third Quarter 2014 Financial Results Conference Call Nov 03 2014 
Tribute Pharmaceuticals Receives Uracyst(R) Patent in Europe Oct 30 2014 
Tribute Pharmaceuticals Announces Acquisition of Canadian Rights to Fiorinal®, Fiorinal® C, Visken Oct 15 2014 

More From Other Websites
Tribute Pharmaceuticals Added to the S&P/TSX Venture Composite Index Apr 15 2015
Tribute Pharmaceuticals Added to the S&P/TSX Venture Composite Index Apr 15 2015
Tribute Pharmaceuticals to Participate at Laurentian Bank Securities Annual Investor Conference Apr 02 2015
Tribute Pharmaceuticals to Participate at Laurentian Bank Securities Annual Investor Conference Apr 02 2015
Tribute Raises US$2.7 Million Through the Exercise of Warrants Mar 19 2015
Tribute Pharmaceuticals Announces Strong 2014 Fourth Quarter and Year End Results Mar 19 2015
Tribute Raises US$2.7 Million Through the Exercise of Warrants Mar 19 2015
TRIBUTE PHARMACEUTICALS CANADA INC. Financials Mar 11 2015
10-K for Tribute Pharmaceuticals Canada, Inc. Mar 05 2015
TBUFF: Strong 2014 But Expect Significant Ramp in 2015 Mar 05 2015
TRIBUTE PHARMACEUTICALS CANADA INC. Files SEC form 8-K, Unregistered Sale of Equity Securities Mar 04 2015
TRIBUTE PHARMACEUTICALS CANADA INC. Files SEC form 8-K, Results of Operations and Financial... Mar 03 2015
Tribute Pharmaceuticals Announces Strong 2014 Fourth Quarter and Year End Results Mar 03 2015
Tribute Pharmaceuticals to Host Fourth Quarter and Fiscal Year 2014 Earnings Conference Call and... Mar 02 2015
Tribute Pharmaceuticals Board Members and Management Exercise Series A Warrants Mar 02 2015
Tribute Pharmaceuticals Schedules Fourth Quarter and 2014 Year End Financial Results Conference Call Mar 02 2015
Tribute Pharmaceuticals Board Members and Management Exercise Series A Warrants Mar 02 2015
Tribute Pharmaceuticals Schedules Fourth Quarter and 2014 Year End Financial Results Conference Call Feb 26 2015
TRIBUTE PHARMACEUTICALS CANADA INC. Files SEC form 8-K, Change in Directors or Principal Officers,... Feb 02 2015
Tribute Pharmaceuticals Engages BND Projects Inc. as Investor Relations Service Provider and Grants... Jan 29 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK